Overview of gene therapy for RDEB

RDEB Treatment Revolution

Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disorder caused by mutations in the COL7A1 gene, leading to fragile skin that blisters and wounds easily. Affecting about one in 20,000 births, it primarily impacts children, earning them the moniker 'butterfly children' due to their delicate skin. Without effective treatments, patients endure lifelong pain, infections, scarring, and a heightened risk of skin cancer, with many not surviving beyond their 30s.

The landscape changed dramatically in April 2025 when the FDA approved Zevaskyn, developed by Abeona Therapeutics. This autologous therapy involves harvesting a patient's skin cells, genetically correcting them to produce functional type VII collagen, and grafting them back as sheets onto wounds. Phase 3 trials showed 81% of treated wounds healing by at least 50% at six months, compared to 16% with standard care. By December 2025, the first commercial patient was treated at Stanford, signaling the therapy's entry into clinical practice.

Yet, this breakthrough comes amid broader challenges in the cell and gene therapy sector. Companies like Bluebird Bio faced financial strains, leading to privatization in 2025, while others such as Takeda and Galapagos wound down operations by early 2026. For Zevaskyn, a permanent J-code assigned by CMS, effective January 1, 2026, streamlines billing and could facilitate insurance coverage. However, the therapy's high cost—potentially exceeding $1 million per treatment—raises questions about equity, especially since RDEB disproportionately affects lower-income families reliant on public insurance.

Non-obvious tensions include the balance between Zevaskyn's one-time surgical application, which provides sustained collagen expression for over two years, and alternatives like Vyjuvek, a topical gel approved in 2023 that requires weekly applications. While Zevaskyn targets large chronic wounds effectively, its invasive nature may deter some patients or strain limited qualified treatment centers. Expanding these centers, as announced in July and December 2025, aims to boost capacity, but regulatory scrutiny on manufacturing and long-term data could slow progress. Surprising data from follow-up studies indicate benefits lasting up to eight years in some cases, yet risks of procedural complications, though low at under 5%, underscore the need for careful patient selection.